Digestive System Diseases Clinical Trial
Official title:
Non-anesthesiologist Administered Propofol Sedation for Colonoscopy - a Randomized Clinical Trial
Verified date | October 2015 |
Source | Hospital Beatriz Ângelo |
Contact | n/a |
Is FDA regulated | No |
Health authority | Portugal: Data Protection Agency |
Study type | Interventional |
Propofol is the preferred sedation for colonoscopy. There is debate on the safety of the
administration of propofol by non-anesthesiologists, despite moderate quality evidence that
support its' use.
There is only one small trial of a direct comparison of propofol sedation by
anesthesiologists versus non-anesthesiologists.
Our aim is to compare the incidence of sedation related adverse events, the procedural
quality indicators, times (onset, recovery, discharge) and patient satisfaction between
non-anesthesiologist administered propofol sedation (NAAP) sedation and anesthesiologist
propofol sedation.
A randomized clinical trial with the incidence of sedation related minor adverse events as
primary endpoint will be conducted. Secondary endpoints include procedure quality
indicators, propofol dosage and patient satisfaction.
A sample size of 330 subjects (2 arms of 165 patients) will be needed in order to obtain 90%
power and a 5% significance level to exclude a 15% difference (15 - 30%) in adverse events
incidence, estimated from our pilot experience. The sample size was adjusted for a 2%
cross-over rate.
Informed and consenting patients undergoing colonoscopy examinations will be randomly
assigned to one of two arms. One group will be sedated by an anesthesiologist according to a
protocol of propofol mono-sedation. The other group will be sedated with propofol boluses,
according to the European Society of Gastrointestinal Endoscopy (ESGE) NAAP guideline, with
a 3-man team consisting of one endoscopist, one endoscopy nurse and a sedation nurse,
trained in NAAP and exclusively dedicated to sedation and patient monitoring.
Status | Completed |
Enrollment | 277 |
Est. completion date | August 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Referred for elective colonoscopy as outpatients - Must be able to provide the informed consent Exclusion Criteria: - American Society of Anaesthesiologists (ASA) class >2 - Pregnant women - Difficult airway predictors (more than 2 ou Mallampati >3) - Allergy to propofol or its' components - IV drugs abuse |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Portugal | Hospital Beatriz Ângelo | Loures |
Lead Sponsor | Collaborator |
---|---|
Hospital Beatriz Ângelo |
Portugal,
Dumonceau JM, Riphaus A, Aparicio JR, Beilenhoff U, Knape JT, Ortmann M, Paspatis G, Ponsioen CY, Racz I, Schreiber F, Vilmann P, Wehrmann T, Wientjes C, Walder B; NAAP Task Force Members. European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: Non-anesthesiologist administration of propofol for GI endoscopy. Endoscopy. 2010 Nov;42(11):960-74. doi: 10.1055/s-0030-1255728. Epub 2010 Nov 11. — View Citation
Dumonceau JM, Riphaus A, Beilenhoff U, Vilmann P, Hornslet P, Aparicio JR, Dinis-Ribeiro M, Giostra E, Ortmann M, Knape JT, Ladas S, Paspatis G, Ponsioen CY, Racz I, Wehrmann T, Walder B. European curriculum for sedation training in gastrointestinal endoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA). Endoscopy. 2013 Jun;45(6):496-504. doi: 10.1055/s-0033-1344142. Epub 2013 May 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Minor adverse events | Minor adverse events as defined by the International Sedation Task Force, including peripheral O2 saturation between 75-90% for less than 60 seconds, apnea, airway obstruction, sedation failure, allergic reaction without anaphylaxis, convulsion, brady/tachycardia and hypo/hypertension (>25% change from baseline) | During the sedation period | Yes |
Secondary | Propofol dosage | Total propofol dosage | During the colonoscopy - an estimated mean time of 20 minutes | No |
Secondary | Patient satisfaction | A 10 point visual scale on pain | Before discharge - estimated mean recovery time of 1 hour | No |
Secondary | colonoscopy quality indicators | Colonoscopy quality indicators: time to cecum, withdrawal time, adenoma detection rate | During the procedure | No |
Secondary | Patient satisfaction 2 | A 5 point likert scale on patient satisfaction with the sedation | Before discharge - estimated mean recovery time of 1 hour | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05294107 -
Intestinal Organoids
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01427725 -
Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
|
||
Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
Active, not recruiting |
NCT05602935 -
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
|
Phase 2 | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05322486 -
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
|
||
Completed |
NCT02267681 -
Opioid Effects on Cognitive Function Following Colonoscopy
|
Phase 4 | |
Terminated |
NCT02503631 -
Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
|
||
Completed |
NCT01600209 -
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
|
N/A | |
Completed |
NCT01260168 -
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
|
N/A | |
Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
Completed |
NCT01463319 -
Warm Water and Unsedated Colonoscopy
|
Phase 0 | |
Terminated |
NCT00577772 -
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
|
N/A | |
Suspended |
NCT00606788 -
Therapy Study of Automated Protocolized vs. Physician-Directed Non-Protocolized Weaning
|
N/A | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Recruiting |
NCT03776760 -
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
|
||
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 |